- Home
- COLL vs OCS Comparison
COLL vs OCS Comparison
Compare COLL & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- OCS
- Stock Information
- Founded
- COLL 2002
- OCS 2003
- Country
- COLL United States
- OCS Switzerland
- Employees
- COLL N/A
- OCS N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- COLL Health Care
- OCS Health Care
- Exchange
- COLL Nasdaq
- OCS Nasdaq
- Market Cap
- COLL 1.1B
- OCS 1.0B
- IPO Year
- COLL 2015
- OCS N/A
- Fundamental
- Price
- COLL $45.49
- OCS $19.22
- Analyst Decision
- COLL Strong Buy
- OCS Strong Buy
- Analyst Count
- COLL 5
- OCS 5
- Target Price
- COLL $45.40
- OCS $39.80
- AVG Volume (30 Days)
- COLL 520.4K
- OCS 116.3K
- Earning Date
- COLL 11-06-2025
- OCS 11-10-2025
- Dividend Yield
- COLL N/A
- OCS N/A
- EPS Growth
- COLL N/A
- OCS N/A
- EPS
- COLL 1.63
- OCS N/A
- Revenue
- COLL $757,067,000.00
- OCS $991,999.00
- Revenue This Year
- COLL $21.41
- OCS $32.89
- Revenue Next Year
- COLL $3.28
- OCS $1,043.16
- P/E Ratio
- COLL $28.29
- OCS N/A
- Revenue Growth
- COLL 26.34
- OCS N/A
- 52 Week Low
- COLL $23.23
- OCS $14.00
- 52 Week High
- COLL $48.18
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- COLL 74.50
- OCS 45.00
- Support Level
- COLL $35.26
- OCS $18.86
- Resistance Level
- COLL $48.18
- OCS $19.87
- Average True Range (ATR)
- COLL 1.74
- OCS 0.70
- MACD
- COLL 0.93
- OCS -0.16
- Stochastic Oscillator
- COLL 80.20
- OCS 11.38
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.